In Brief: Gliatech Inc.
This article was originally published in The Gray Sheet
Executive Summary
Gliatech Inc.: Reports results of two clinical studies demonstrating the clinical effectiveness of the firm's Adcon-L and Adcon-T/N resorbable, barrier gels in "inhibiting postoperative adhesions and improving surgical outcome." Presented the week of Aug. 18 at the International Society of Orthopedic and Trauma Surgeons World Congress in Amsterdam, one study of 267 first-time lumbar discetomy patients shows that Adcon-L "significantly decreased peridural scar and improved patient outcome by reducing the incidence of activity related pain while performing typical activities of daily living." In a study involving 32 hand tenolysis procedures, patients treated with Adcon-T/N "showed a 118% greater improvement in digital range of motion compared to controls." Gliatech has clinical trials ongoing in the U.S. for the two gel-based products...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.